Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(3):432–435. doi: 10.1038/bjc.1997.71

Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.

R de Wit 1, R Sylvester 1, C Tsitsa 1, P H de Mulder 1, D T Sleyfer 1, W W ten Bokkel Huinink 1, S B Kaye 1, A T van Oosterom 1, E Boven 1, K Vermeylen 1, G Stoter 1
PMCID: PMC2063372  PMID: 9020492

Abstract

We investigated the prognostic value of the serum half-life of human chorionic gonadotrophin (HCG) and alpha-fetoprotein (AFP) during induction chemotherapy and the relative prognostic importance of initial marker concentrations and marker half-life. Marker half-lives were calculated using two abnormal values observed between day 8 and day 22 of the first chemotherapy cycle. Moreover, analyses were carried out using day 43 as the second measurement point. Treatment failure at any time was chosen as the end point. The relative prognostic influence of marker half-lives and initial marker concentrations was tested in univariate and multivariate analyses. Half-lives were considered to be prolonged if > 3 days for HCG and > 6 days for AFP. In addition, we separated patients into those with half-lives > 6 days for HCG and those with half-lives > 10 days for AFP to examine whether these long half-lives were associated with a poor prognosis. A group of 669 patients treated with cisplatin combination chemotherapy was studied. Forty-two per cent of the patients had normal HCG and 37% had normal AFP at the start of chemotherapy. At day 22, HCG was still elevated in 138 patients and AFP in 211. At day 43, the numbers of these patients were 35 and 80 respectively. Based on the measurements obtained on day 8 and day 22, a half-life of HCG > 3 days or > 6 days and/or a half-life AFP > 6 days or > 10 days did not accurately predict treatment failure (P=0.413 and P=0.851, respectively; values obtained using tests for trend). However, initial marker concentrations of HCG and/or AFP > 1000 IU l(-1) were highly significant prognosticators for treatment failure (P=0.001 and P < 0.001 respectively), independent of half-life values. Half-lives calculated with the values obtained on day 43 did not contribute to the accuracy of the prediction of treatment failure. We conclude that half-lives of HCG and AFP during induction chemotherapy are inaccurate parameters for the prediction of treatment failure. In contrast, initial serum concentrations of HCG and AFP are highly significant in the prediction of unfavourable treatment outcome.

Full text

PDF
432

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aass N., Klepp O., Cavallin-Stahl E., Dahl O., Wicklund H., Unsgaard B., Baldetorp L., Ahlström S., Fosså S. D. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. J Clin Oncol. 1991 May;9(5):818–826. doi: 10.1200/JCO.1991.9.5.818. [DOI] [PubMed] [Google Scholar]
  2. Bajorin D., Katz A., Chan E., Geller N., Vogelzang N., Bosl G. J. Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies. J Clin Oncol. 1988 May;6(5):786–792. doi: 10.1200/JCO.1988.6.5.786. [DOI] [PubMed] [Google Scholar]
  3. Birch R., Williams S., Cone A., Einhorn L., Roark P., Turner S., Greco F. A. Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol. 1986 Mar;4(3):400–407. doi: 10.1200/JCO.1986.4.3.400. [DOI] [PubMed] [Google Scholar]
  4. Bosl G. J., Geller N. L., Cirrincione C., Vogelzang N. J., Kennedy B. J., Whitmore W. F., Jr, Vugrin D., Scher H., Nisselbaum J., Golbey R. B. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res. 1983 Jul;43(7):3403–3407. [PubMed] [Google Scholar]
  5. Droz J. P., Kramar A., Ghosn M., Piot G., Rey A., Theodore C., Wibault P., Court B. H., Perrin J. L., Travagli J. P. Prognostic factors in advanced nonseminomatous testicular cancer. A multivariate logistic regression analysis. Cancer. 1988 Aug 1;62(3):564–568. doi: 10.1002/1097-0142(19880801)62:3<564::aid-cncr2820620321>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  6. Hitchins R. N., Newlands E. S., Smith D. B., Begent R. H., Rustin G. J., Bagshawe K. D. Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis. Br J Cancer. 1989 Feb;59(2):236–242. doi: 10.1038/bjc.1989.48. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Levi J. A., Thomson D., Sandeman T., Tattersall M., Raghavan D., Byrne M., Gill G., Harvey V., Burns I., Snyder R. A prospective study of cisplatin-based combination chemotherapy in advanced germ cell malignancy: role of maintenance and long-term follow-up. J Clin Oncol. 1988 Jul;6(7):1154–1160. doi: 10.1200/JCO.1988.6.7.1154. [DOI] [PubMed] [Google Scholar]
  8. Mead G. M., Stenning S. P., Parkinson M. C., Horwich A., Fossa S. D., Wilkinson P. M., Kaye S. B., Newlands E. S., Cook P. A. The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol. 1992 Jan;10(1):85–94. doi: 10.1200/JCO.1992.10.1.85. [DOI] [PubMed] [Google Scholar]
  9. Motzer R. J., Mazumdar M., Gulati S. C., Bajorin D. F., Lyn P., Vlamis V., Bosl G. J. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst. 1993 Nov 17;85(22):1828–1835. doi: 10.1093/jnci/85.22.1828. [DOI] [PubMed] [Google Scholar]
  10. Peckham M. J., Horwich A., Easton D. F., Hendry W. F. The management of advanced testicular teratoma. Br J Urol. 1988 Jul;62(1):63–68. doi: 10.1111/j.1464-410x.1988.tb04268.x. [DOI] [PubMed] [Google Scholar]
  11. Roth B. J., Greist A., Kubilis P. S., Williams S. D., Einhorn L. H. Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up. J Clin Oncol. 1988 Aug;6(8):1239–1247. doi: 10.1200/JCO.1988.6.8.1239. [DOI] [PubMed] [Google Scholar]
  12. Stevens M. J., Norman A. R., Dearnaley D. P., Horwich A. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma. J Clin Oncol. 1995 Jan;13(1):87–92. doi: 10.1200/JCO.1995.13.1.87. [DOI] [PubMed] [Google Scholar]
  13. Stoter G., Koopman A., Vendrik C. P., Struyvenberg A., Sleyfer D. T., Willemse P. H., Schraffordt Koops H., van Oosterom A. T., ten Bokkel Huinink W. W., Pinedo H. M. Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol. 1989 Aug;7(8):1099–1104. doi: 10.1200/JCO.1989.7.8.1099. [DOI] [PubMed] [Google Scholar]
  14. Stoter G., Sylvester R., Sleijfer D. T., ten Bokkel Huinink W. W., Kaye S. B., Jones W. G., van Oosterom A. T., Vendrik C. P., Spaander P., de Pauw M. Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from a European Organization for Research on Treatment of Cancer Multiinstitutional Phase III Study. Cancer Res. 1987 May 15;47(10):2714–2718. [PubMed] [Google Scholar]
  15. Toner G. C., Geller N. L., Tan C., Nisselbaum J., Bosl G. J. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res. 1990 Sep 15;50(18):5904–5910. [PubMed] [Google Scholar]
  16. Vogelzang N. J., Lange P. H., Goldman A., Vessela R. H., Fraley E. E., Kennedy B. J. Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors. Cancer Res. 1982 Nov;42(11):4855–4861. [PubMed] [Google Scholar]
  17. de Wit R., Stoter G., Sleijfer D. T., Kaye S. B., de Mulder P. H., ten Bokkel Huinink W. W., Spaander P. J., de Pauw M., Sylvester R. Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer. 1995 Jun;71(6):1311–1314. doi: 10.1038/bjc.1995.254. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES